check_circleStudy Completed

Bayer Identifier:

18857

ClinicalTrials.gov Identifier:

Not Available

EudraCT Number:

Not Available

EU CT Number:

Not Available
Utilization and Continuation Rates of Skyla

Trial purpose

Key Participants Requirements

Sex

N/A

Age

15 - 44 Years
  • -

  • -

Trial summary

Enrollment Goal
99999
Trial Dates
August 2016 - February 2017
Phase
N/A
Could I Receive a placebo
N/A
Products
Skyla (Levonorgestrel, BAY86-5028)
Accepts Healthy Volunteer
Yes

Where to participate

StatusInstitutionLocation
Completed
N/A, United States

Primary Outcome

  • Twelve-month discontinuation rates of LNG-IUS 8 and ENG implant using a large US claims database

Trial design

A Retrospective Analysis to Estimate the 12-month Continuation Rates of Levonorgestrel Intrauterine System (LNG-IUS) 13.5 mg and Subdermal Etonogestrel (ENG) Implant in a Commercially-Insured Population in the U.S.
Trial Type
Observational
Intervention Type
N/A
Trial Purpose
N/A
Allocation
N/A
Blinding
N/A
Assignment
N/A
Trial Arms
N/A

Additional Information

Click here and search for drug information provided by the FDA.Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.Click here to find results for studies related to Bayer products.